Craig Gibbs
About Craig Gibbs
Craig Gibbs is the CEO with over 31 years of experience in the biopharmaceutical industry, known for his significant contributions to the development and commercialization of 12 FDA-approved drugs.
Craig Gibbs - Chief Executive Officer
Craig Gibbs serves as the Chief Executive Officer, bringing over 31 years of experience in the biopharmaceutical industry. His extensive career encompasses high-level leadership roles and notable contributions in the development and commercialization of biopharmaceutical products. He is recognized for his strategic insight and dedication to advancing the field.
Craig Gibbs' Education and Expertise
Craig Gibbs holds a Ph.D. in Molecular Biology from the University of Glasgow, Scotland, and a B.Sc. (Hons) in Biochemistry from Massey University, New Zealand. He further expanded his expertise with an M.B.A. from Golden Gate University in San Francisco, CA. His academic background provides a strong foundation for his extensive contributions to biopharmaceutical research and business strategy.
Board Memberships and Affiliations of Craig Gibbs
Craig Gibbs actively participates in the governance of several organizations. He serves on the Boards of Directors for Aridis Pharmaceuticals, Inipharm Inc., and the Northern California Chapter of the Leukemia and Lymphoma Society. His board memberships underscore his commitment to the advancement of biopharmaceutical research and patient advocacy.
Craig Gibbs' Career at Gilead Sciences
During his 21 years at Gilead Sciences, Craig Gibbs held various leadership roles, including Vice President of Commercial Strategy. His tenure at Gilead involved significant contributions to the development, launch, and commercialization of 12 FDA-approved drugs, highlighting his impact on the company's growth and success.
Scientific Contributions by Craig Gibbs
Craig Gibbs has published over 50 scientific articles and is an inventor on three issued patents. His research and innovations have made substantial contributions to the field of biopharmaceuticals. His early career included a postdoctoral fellowship in the Protein Engineering Department at Genentech, further establishing his expertise in molecular biology.